Ella Waters

Ms. Ella Waters

The Open University, Milton Keynes, UK
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2022 in Cancers
Verified
Journal Article
Open access
PDF file
LBLucie J. Bilton
Lucie J. Bilton
CWChloe Warren
Chloe Warren
RHRebecca M. Humphries
Rebecca M. Humphries
SKShannon Cartay Kalsi
Shannon Cartay Kalsi
EWElla Waters
Ella Waters
MWMark Wade
Mark Wade
Chromobox 2 (CBX2) is a chromatin-binding component of polycomb repressive complex 1, which causes gene silencing. CBX2 expression is elevated in triple-negative breast cancer (TNBC), for which there are few therapeutic options. Here, we aimed to investigate the functional role of CBX2 in TNBC. CBX2 knockdown in TNBC models reduced cell numbers, which was rescued by ectopic expression of wild-type CBX2 but not a chromatin binding-deficient mutant. Blocking CBX2 chromatin interactions using the inhibitor SW2_152F also reduced cell growth, suggesting CBX2 chromatin binding is crucial for TNBC progression. RNA sequencing and gene set enrichment analysis of CBX2-depleted cells identified downregulation of oncogenic signalling pathways, including mTORC1 and E2F signalling. Subsequent analysis identified that CBX2 represses the expression of mTORC1 inhibitors and the tumour suppressor RBL2. RBL2 repression, in turn, inhibits DREAM complex activity. The DREAM complex inhibits E2F signalling, causing cell senescence; therefore, inhibition of the DREAM complex via CBX2 may be a key oncogenic driver. We observed similar effects in oestrogen receptor-positive breast cancer, and analysis of patient datasets suggested CBX2 inhibits RBL2 activity in other cancer types. Therapeutic inhibition of CBX2 could therefore repress mTORC1 activation and promote DREAM complex-mediated senescence in TNBC and could have similar effects in other cancer types.

22 October 2021 in Epigenomics
Verified
Journal Article
Open access
EWElla Waters
Ella Waters
PPPerla Pucci
Perla Pucci
MHMark Hirst
Mark Hirst
SCSimon Chapman
Simon Chapman
Yuzhuo WangYuzhuo Wang
Yuzhuo Wang
CHChristopher J Heath
Christopher J Heath
Long noncoding RNAs (lncRNAs) have a wide range of functions in health and disease, but many remain uncharacterized because of their complex expression patterns and structures. The genetic loci enc...

Verified
Journal Article
Open access
PDF file
DRDavid Roig-Carles
David Roig-Carles
HJHolly Jackson
Holly Jackson
KLKatie Loveson
Katie Loveson
AMAlan Mackay
Alan Mackay
RMRebecca Mather
Rebecca Mather
FCFrancesco Crea
Francesco Crea
Diffuse intrinsic pontine glioma (DIPG) is an incurable paediatric malignancy. Identifying the molecular drivers of DIPG progression is of the utmost importance. Long non-coding RNAs (lncRNAs) represent a large family of disease- and tissue-specific transcripts, whose functions have not yet been elucidated in DIPG. Herein, we studied the oncogenic role of the development-associated H19 lncRNA in DIPG. Bioinformatic analyses of clinical datasets were used to measure the expression of H19 lncRNA in paediatric high-grade gliomas (pedHGGs). The expression and sub-cellular location of H19 lncRNA were validated in DIPG cell lines. Locked nucleic acid antisense oligonucleotides were designed to test the function of H19 in DIPG cells. We found that H19 expression was higher in DIPG vs. normal brain tissue and other pedHGGs. H19 knockdown resulted in decreased cell proliferation and survival in DIPG cells. Mechanistically, H19 buffers let-7 microRNAs, resulting in the up-regulation of oncogenic let-7 target (e.g., SULF2 and OSMR). H19 is the first functionally characterized lncRNA in DIPG and a promising therapeutic candidate for treating this incurable cancer.

27 November 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EWElla Waters
Ella Waters
PPPerla Pucci
Perla Pucci
RRRuman Rahman
Ruman Rahman
AYAnna P. Yatsyshyna
Anna P. Yatsyshyna
HPHarry Porter
Harry Porter
FCFrancesco Crea
Francesco Crea
The long non-coding RNA (lncRNA), HAR1A is emerging as a putative tumour suppressor. In non-neoplastic brain cells, REST suppresses HAR1A expression. In gliomas REST acts as an oncogene and is a potential therapeutic target. It is therefore conceivable that REST promotes glioma progression by down-regulating HAR1A. To test this hypothesis, glioma clinical databases were analysed to study: (I) HAR1A/REST correlation; (II) HAR1A and REST prognostic role; (III) molecular pathways associated with these genes. HAR1A expression and subcellular localization were studied in glioblastoma and paediatric glioma cells. REST function was also studied in these cells, by observing the effects of gene silencing on: (I) HAR1A expression; (II) cancer cell proliferation, apoptosis, migration; (III) expression of neural differentiation genes. The same phenotypes (and cell morphology) were studied in HAR1A overexpressing cells. Our results show that REST and HAR1A are negatively correlated in gliomas. Higher REST expression predicts worse prognosis in low-grade gliomas (the opposite is true for HAR1A). REST-silencing induces HAR1A upregulation. HAR1A is primarily detected in the nucleus. REST-silencing dramatically reduces cell proliferation and induces apoptosis, but HAR1A overexpression has no major effect on investigated cell phenotypes. We also show that REST regulates the expression of neural differentiation genes and that its oncogenic function is primarily HAR1A-independent.

3 April 2023
Verified
Other
Open access
TFThilini R. Fernando
Thilini R. Fernando
NRNorma I. Rodriguez-Malave
Norma I. Rodriguez-Malave
EWElla Waters
Ella Waters
WYWeihong Yan
Weihong Yan
DCDavid Casero
David Casero
DRDinesh S. Rao
Dinesh S. Rao
Supplemental Tables 1 - 4. Supplemental Table 1: Patient characteristics for use in this study. Supplemental Table 2: Correlational bivariate analyses between ordinal variable clinicopathologic characteristics. Supplemental Table 3: Results of Cox Regression analysis using BALR-2, Translocation, and Prednisone Response as co-variates.

12 September 2022 in Research Square
Verified
Preprint
Open access
PDF file
RWRaymond Whorley
Raymond Whorley
EWElla Waters
Ella Waters
AKAzuma Kalu
Azuma Kalu
FCFrancesco Crea
Francesco Crea
RLRobin Laney
Robin Laney
Background EZH2 is linked to cancer, interacting in various ways with some long non-coding RNAs but not others. It is reasonable to assume that the interacting sequences have physical interaction sites which are not present in the non-interacting ones. We hypothesise that these interaction sites correspond to motifs (short subsequences) which appear in a particular order. We have developed software to find such ordered motif combinations. The software can also suggest where larger scale similarities between and within lncRNAs may be found by calculating mean information content. Results We investigated motifs of length 5 to 11, with up to 3 motifs per combination, in murine lncRNAs. Appearing in 13 out of 59 interacting lncRNAs, 4 combinations comprising 2 motifs of length 6 have been identified as EZH2 interaction site candidates which can be further investigated. Conclusions Our predictions can be tested experimentally to ascertain whether or not these combinations really do constitute interaction sites. For example, genome editing can be employed to measure the cellular and molecular effects of ablating these sequences in the EZH2-interacting lncRNAs. In addition, computational and advanced microscopy methodologies can be employed to locate these motifs within the tri-dimensional structure of these lncRNAs.